In this edition of Hardman Talks, CEO Keith Hiscock sits down with Dr Martin Hall, Head of Life Sciences at Hardman & Co, to discuss the structural and financial pressures facing the UK healthcare sector. Based on Hardman & Co’s 2024 sector review, Martin explains how the sector’s third consecutive year of underperformance reflects a range of factors: persistent funding shortfalls, institutional investor withdrawal and an increasing number of companies delisting or entering administration.
Martin outlines the implications of these trends for the long-term viability of the sector on public markets, the risks to retail shareholders, and the uphill battle small-cap healthcare companies face in securing development capital. Despite the challenges, he reiterates the strength of UK healthcare innovation – although its survival increasingly depends upon urgent systemic change.
Watch the interview now to find out more, and read Martin’s Healthcare Index report for more detail.
